Article Text
Abstract
Rare diseases pose a particular priority setting problem. The UK gives rare diseases special priority in healthcare priority setting. Effectively, the National Health Service is willing to pay much more to gain a quality-adjusted life-year related to a very rare disease than one related to a more common condition. But should rare diseases receive priority in the allocation of scarce healthcare resources? This article develops and evaluates four arguments in favour of such a priority. These pertain to public values, luck egalitarian distributive justice the epistemic difficulties of obtaining knowledge about rare diseases and the incentives created by a higher willingness to pay. The first is at odds with our knowledge regarding popular opinion. The three other arguments may provide a reason to fund rare diseases generously. However, they are either overinclusive because they would also justify funding for many non-rare diseases or underinclusive in the sense of justifying priority for only some rare diseases. The arguments thus fail to provide a justification that tracks rareness as such.
- ethics
- health care for specific diseases/groups
- health economics
- philosophical ethics
- allocation of health care resources
Data availability statement
There are no data in this work.
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Should rare diseases get special treatment?
- Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthy life year
- Solidarity, justice and unconditional access to healthcare
- A framework for luck egalitarianism in health and healthcare
- Rare neurological diseases: a practical approach to management
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Distributive justice and the harm to medical professionals fighting epidemics
- How the past matters for the future: a luck egalitarian sustainability principle for healthcare resource allocation
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence